ELTX - Company ID 0001601485
The table below shows Elicio Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$11.64M | -$10.12M | -$12.12M | -$8.14M | -$15.65M | -$12.55M |
| Capital expenditure | - | - | $0.00 | $17.00K | $0.00 | $41.00K |
| Investing cash flow | - | $0.00 | $3.00K | -$17.00K | $0.00 | -$41.00K |
| Dividends paid | - | - | - | - |
Elicio Therapeutics, Inc. reported operating cash flow of -$36.95M for fiscal year 2025. That is up 0.3% from -$37.07M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$22.89M (FY 2020) to -$36.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $8.03M | $10.33M | $11.02M | $10.04M | -$14.00K | $108.44M |